Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine"
DOI: 10.1007/s12020-020-02424-z
Abstract: Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further… read more here.
Keywords: lanreotide autogel; autogel 120; control; extended dosing ... See more keywords
A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.
Sign Up to like & getrecommendations! Published in 2022 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2022.108775
Abstract: BACKGROUND In addition to 2-weekly nivolumab 240 mg or 3-weekly pembrolizumab 200 mg, extended dosing intervals of 4-weekly nivolumab 480 mg or 6-weekly pembrolizumab 200 mg were approved. To date, the clinical safety of the extended dosing schedules of… read more here.
Keywords: safety extended; pembrolizumab; solid tumors; extended dosing ... See more keywords
Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14152
Abstract: In clinical trials, recombinant factor IX fusion protein (rFIXFc) has demonstrated safety, efficacy and prolonged activity with extended dosing intervals for treatment of haemophilia B. read more here.
Keywords: recombinant factor; extended dosing; protein rfixfc; factor fusion ... See more keywords